Ipsen Buys Botulinum Toxin Specialist Syntaxin for $206M
LONDON The UK botulinum toxin specialist Syntaxin Ltd. is to be acquired by research partner and equity investor Ipsen SA in a deal that potentially is worth €158 million (US$205.8 million), with €28 million to be paid up front, and the remainder tied to development and commercialization milestones.
Separately, the shareholders are in line to receive any payments made on Syntaxin's Phase II lead program, a treatment for post-herpetic neuralgia, which is partnered with Allergan Inc.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST